Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing:
“Changing the paradigm of how research is funded and how care is funded, I think makes us all a bit nervous,” said Lynch, president and director of Fred Hutch Cancer Center, an NCI-designated Comprehensive Cancer Center in Seattle.
“To stop that flow of ideas from universities and from hospitals to pharmaceutical companies, it is going to basically hand the future of biopharma to countries outside of the United States,” he said.
